Wed, 17 Sep 2025

Wed, 17 Sep 2025 GSK pledges $30bn US investment as UK's pharma woes deepen

The company is the latest pharma firm to have either reduced spending in the UK or diverted it to the US.
British pharmaceutical firm GSK has announced a $30bn investment plan over five years in research and manufacturing in the US. This includes:
* A new $1.2bn factory in Pennsylvania for respiratory disease and cancer medicines, set to start construction next year
* Development of AI and digital technology tools across its five American manufacturing sites
* Investment supporting supply chain and drug research efforts The move is seen as a response to pressure from the US Trump administration for companies to relocate production to the country. GSK also confirmed it will continue investing in its UK base, with £1.5bn annual spending on R&D.
  >>